Sutent Európai Unió - dán - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastiske midler - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Vyndaqel Európai Unió - dán - EMA (European Medicines Agency)

vyndaqel

pfizer europe ma eeig - tafamidis - amyloidose - andre narkotika stoffer - vyndaqel er indiceret til behandling af transthyretinamyloidose hos voksne patienter med fase 1-symptomatisk polyneuropati for at forsinke perifer neurologisk nedsat funktion.

Meropenem "Pfizer" 500 mg pulver til injektions-/infusionsvæske, opløsning Dánia - dán - Lægemiddelstyrelsen (Danish Medicines Agency)

meropenem "pfizer" 500 mg pulver til injektions-/infusionsvæske, opløsning

pfizer aps - meropenem (trihydrat) - pulver til injektions-/infusionsvæske, opløsning - 500 mg